Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models

Endocrinology

Volumn 155, Issue 8, 2014, Pages 3146-3159

  Caldwell, A S L ^a   Middleton, L J ^a   Jimenez, M ^a   Desai, R ^a   McMahon, A C ^a   Allan, C M ^a   Handelsman, D J ^a   Walters, K A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; BODY WEIGHT; CHOLESTEROL; DISEASE MODELS, ANIMAL; ESTROUS CYCLE; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HYPERANDROGENISM; INSULIN RESISTANCE; LIVER; LUTEINIZING HORMONE; MALE; MICE; MICE, INBRED C57BL; MYOCARDIUM; ORGAN SIZE; OVARY; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES;

EID: 84904968657     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1196     Document Type: Article

References (65)

1. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012; 97:28-38.e25.
2. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009; 91:456-488.
3. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005; 11: 357-374.
4. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev En-docrinol. 2011; 7:219-231.
5. Padmanabhan V, Veiga-Lopez A. Sheep models of polycystic ovary syndrome phenotype. Mol Cell Endocrinol. 2013; 373:8-20.
6. Walters KA, Allan CM, Handelsman DJ. Rodent models for human polycystic ovary syndrome. Biol Reprod. 2012; 86:149, 1-149.
7. Franks S. Animal modelsand the developmental origins of polycystic ovary syndrome: increasing evidence for the role of androgens in programming reproductive and metabolic dysfunction. Endocrinology. 2012; 153:2536-2538.
8. Manikkam M, Steckler TL, Welch KB, Inskeep E.K., Padmanabhan V. Fetal programming: prenatal testosterone treatment leads to follicular persistence/luteal defects; partial restoration of ovarian function by cyclic progesterone treatment. Endocrinology. 2006; 147: 1997-2007
9. Smith P, Steckler TL, Veiga-Lopez A, Padmanabhan V. Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep. Biol Reprod. 2009; 80:726-736.
10. Padmanabhan V, Veiga-Lopez A, Abbott DH, Recabarren S.E., Herkimer C. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology. 2010; 151:595-605.
11. Abbott DH, Nicol LE, Levine JE, Xu N, Goodarzi M.O., Dumesic DA. Nonhuman primate models of polycystic ovary syndrome. Mol Cell Endocrinol. 2013; 373:21-28.
12. Dumesic DA, Abbott DH, Eisner JR, Goy RW. Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertil Steril. 1997; 67:155-163.
13. van Houten EL, Kramer P, McLuskey A, Karels B., Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology. 2012; 153:2861-2869.
14. Mannerås L, Cajander S, Holmäng A, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology. 2007; 148:3781-3791.
15. Tyndall V, Broyde M, Sharpe R., Welsh M, Drake AJ, McNeilly AS. Effect of androgen treatment during foetal and/or neonatal life on ovarian function in prepubertal and adult rats. Reproduction. 2012; 143:21-33.
16. Wu XY, Li ZL, Wu CY, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats. Endocr J. 2010; 57:201-209.
17. Roland AV, Nunemaker CS, Keller SR, Moenter SM. Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol. 2010; 207:213-223.
18. Beloosesky R, Gold R, Almog B, et al. Induction of polycystic ovary by testosterone in immature female rats: modulation of apoptosis and attenuation of glucose/insulin ratio. Int J Mol Med. 2004; 14: 207-215.
19. Edwards DA. Neonatal administration of androstenedione, testosterone or testosterone propionate: effects on ovulation, sexual receptivity and aggressive behavior in female mice. Physiol Behav. 1971; 6:223-228.
20. Sullivan SD, Moenter SM. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci USA. 2004; 101: 7129-7134.
21. Sander V, Luchetti CG, Solano ME, et al. Role of the N, N'-dim-ethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 2006; 131:591-602.
22. Familiari G, Toscano V, Motta PM. Morphological studies of polycystic mouse ovaries induced by dehydroepiandrosterone. Cell Tissue Res. 1985; 240:519-528.
23. Ward RC, Costoff A, Mahesh VB. The induction of polycystic ovaries in mature cycling rats by the administration of dehydroepiandrosterone (DHA). Biol Reprod. 1978; 18:614-623.
24. Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec. 1991; 231:185-192.
25. Kafali H, Iriadam M, Ozardali I, Demir N. Letrozole-inducedpolycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res. 2004; 35:103-108.
26. Sasikala SL, Shamila S. Unique rat model exhibiting biochemical fluctuations of letrozole induced polycystic ovary syndrome and subsequent treatment with allopathic and ayurvedic medicines. J Cell Tissue Res. 2009; 9:2013-2017.
27. Linder CC. Genetic variables that influence phenotype. ILAR J. 2006; 47:132-140.
28. Walters KA, Allan CM, Jimenez M, et al. Female mice haploinsuf-ficient for an inactivated androgen receptor (AR) exhibit age-dependent defects that resemble the AR null phenotype of dysfunctional late follicle development, ovulation, and fertility. Endocrinology. 2007; 148:3674-3684.
29. Simanainen U, Gao YR, Walters KA, et al. Androgen resistance in female mice increases susceptibility to DMBA-induced mammary tumors. Horm Cancer. 2012; 3:113-124.
30. Singh J, O'Neill C, Handelsman DJ. Induction of spermatogenesis by androgens ingonadotropin-deficient (hpg) mice. Endocrinology. 1995; 136:5311-5321.
31. Stener-Victorin E, Holm G, Labrie F., Nilsson L, Janson PO, Ohlsson C. Are there any sensitive and specific sex steroid markers for poly-cystic ovary syndrome? J Clin Endocrinol Metab. 2010; 95:810-819.
32. Walters KA, Middleton LJ, Joseph SR, et al. Targeted loss of androgen receptor signaling in murine granulosa cells of preantral and antral follicles causes female subfertility. Biol Reprod. 2012; 87:151.
33. Myers M, Britt KL, Wreford NG, Ebling F.J., Kerr JB. Methods for quantifying follicular numbers within the mouse ovary. Reproduction. 2004; 127:569-580.
34. van Casteren JI, Schoonen WG, Kloosterboer HJ. Development of time-resolved immunofluorometric assays for rat follicle-stimulating hormone and luteinizing hormone and application on sera of cycling rats. Biol Reprod. 2000; 62:886-894.
35. Jimenez M, Spaliviero JA, Grootenhuis AJ, Verhagen J, Allan C.M., Handelsman DJ. Validation of an ultrasensitive and specific immu-nofluorometric assay for mouse follicle-stimulating hormone. Biol Reprod. 2005; 72:78-85.
36. Harwood DT, Handelsman DJ. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta. 2009; 409:78-84.
37. McNamara KM, Harwood DT, Simanainen U, Walters KA, Jimenez M, Handelsman DJ. Measurement of sex steroids in murine blood and reproductive tissues by liquid chromatography-tandem mass spectrometry. J Steroid Biochem Mol Biol. 2010; 121:611-618.
38. Brennan-Speranza TC, Henneicke H, Gasparini SJ, et al. Osteo-blasts mediate the adverse effects of glucocorticoids on fuel metabolism. J Clin Invest. 2012; 122:4172-4189.
39. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313-1321.
40. Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006; 29:278-285; discussion 286-290
41. Dowling AR, Nedorezov LB, Qiu X, Marino JS, Hill JW. Genetic factors modulate the impact of pubertal androgen excess on insulin sensitivity and fertility. PLoS One. 2013; 8:e79849.
42. Abbott DH, Padmanabhan V, Dumesic DA. Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. Reprod Biol Endocrinol. 2006; 4:17.
43. Franks S, Stark J, Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update. 2008; 14:367-378.
44. Vendola KA, Zhou J, Adesanya O.O., Weil SJ, Bondy CA. Androgens stimulate early stages of follicular growth in the primateovary. JClin Invest. 1998; 101:2622-2629.
45. Wang H, Andoh K, Hagiwara H., et al. Effect of adrenal and ovarian androgensontype4follicles unresponsivetoFSHin immature mice. Endocrinology. 2001; 142:4930-4936.
46. Murray AA, Gosden RG, Allison V, Spears N. Effect of androgens on the development of mouse follicles growing in vitro. J Reprod Fertil. 1998; 113:27-33.
47. Forsdike RA, Hardy K, Bull L., et al. Disordered follicle development in ovaries of prenatally androgenized ewes. J Endocrinol. 2007; 192: 421-428.
48. West C, Foster DL, Evans NP, Robinson J, Padmanabhan V. Intra-follicular activin availability is altered in prenatally-androgenized lambs. Mol Cell Endocrinol. 2001; 185:51-59.
49. Abbott DH, Dumesic DA, Eisner JR, Colman R.J., Kemnitz JW. Insights into the development of polycystic ovary syndrome (PCOS) from studies in prenatally androgenized female rhesus monkeys. Trends Endocrinol Metab. 1998; 9:62-67.
50. Britt KL, Drummond AE, Cox VA, et al. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aroma-tase) gene. Endocrinology. 2000; 141:2614-2623.
51. Schomberg DW, Couse JF, Mukherjee A, et al. Targeted disruption of the estrogen receptor-alpha gene in female mice: characterization of ovarian responses and phenotype in the adult. Endocrinology. 1999; 140:2733-2744.
52. Kumar TR, Palapattu G, Wang P, et al. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol. 1999; 13:851-865.
53. Luchetti CG, Solano ME, Sander V, et al. Effects of dehydroepi- androsterone on ovarian cystogenesis and immune function. J Re-prod Immunol. 2004; 64:59-74.
54. Mahesh VB, Greenblatt RB. Isolation of dehydroepiandrosterone and 17alpha-hydroxy-delta5-pregenolone from the polycystic ovaries of the Stein-Leventhal syndrome. J Clin Endocrinol Metab. 1962; 22:441-448.
55. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 2006; 580:2917-2921.
56. Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol. 2013; 373:68-76.
57. Chen X, Jia X, Qiao J, Guan Y., Kang J. Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. J Mol Endocrinol. 2013; 50:R21-R37.
58. Wild RA. Dyslipidemia in PCOS. Steroids. 2012; 77:295-299.
59. Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005; 5:70-75.
60. Maliqueo M, Sun M, Johansson J, et al. Continuous administration of a P450 aromatase inhibitor induces polycystic ovary syndrome with a metabolic and endocrine phenotype in female rats at adult age. Endocrinology. 2013; 154:434-445.
61. Roy S, Mahesh VB, Greenblatt RB. Effect of dehydroepiandros-terone and delta4-androstenedione on the reproductive organs of female rats: production of cystic changes in the ovary. Nature. 1962; 196:42-43.
62. Karoli R, Fatima J, Chandra A, Gupta U., Islam FU, Singh G. Prevalence of hepatic steatosis in women with polycystic ovary syndrome. J Hum Reprod Sci. 2013; 6:9-14.
63. Hogg K, Wood C, McNeilly AS, Duncan WC. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One. 2011; 6:e24877.
64. Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41-47.
65. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperan-drogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006; 91:4237-4245.